Mainz Biomed N.V(MYNZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 20.41% | Shs Outstand | 9.1M | Perf Week | -7.24% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 98.95% | Insider Trans | 53.41% | Shs Float | 7.2M | Perf Month | -2.44% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 12.49% | Short Float | 6.49% | Perf Quarter | -21.84% |
| Income | - | P/S | - | EPS this Y | 87.21% | Inst Trans | 10.99% | Short Ratio | 0.97 | Perf Half Y | -49.15% |
| Sales | - | P/B | 2.64 | EPS next 5Y | 88.97% | ROA | - | Short Interest | 0.47M | Perf YTD | -24.63% |
| Book/sh | 0.32 | P/C | 4 | EPS past 3/5Y | 29.88% -52.02% | ROE | - | 52W High | -84.19% ($5.34) | Perf Year | -81.89% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | 15.69% 16.01% | ROIC | - | 52W Low | 54.15% ($0.55) | Perf 3Y | -99.68% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.95% | Gross Margin | - | Volatility(W/M) | 10.71% 15.86% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.43 | EPS Q/Q | -1121.45% | Profit Margin | - | RSI (14) | 49.9 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.52 | Sales Q/Q | - | SMA20 | 13.37% ($0.74) | Beta | 0.28 | Target Price | $14 |
| Payout | - | Debt/Eq | 1.23 | Earnings | 2025/09/03 | SMA50 | -14.49% ($0.98) | Rel Volume | 10.88 | Prev Close | $0.83 |
| Employees | 26 | LT Debt/Eq | 0.44 | EPS/Sales Surpr. | - -58.95% | SMA200 | -40.31% ($1.41) | Avg Volume(3M) | 0.48M | Price | $0.84 |
| IPO | 2021/11/5 | Option/Short | No/Yes | Trades | 5722 | Volume | 5,243,351 | Change | 2.07% |
🔬 Mainz BioMed (MYNZ) is a biotechnology company specializing in the development and clinical testing of saliva- and stool-based genetic test kits for the early detection of cancer diseases such as colorectal cancer, based on molecular diagnostic technology.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded more than usual. That is 1088% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +87.2% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.7%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.5%.
Tap to view numbers
It ranks #40 of 45 in the industry
Based on market cap of $8M.
MYNZ#40 Mainz Biomed N.V $8M PER - 
NDRA#40 ENDRA Life Sciences Inc $7M PER - 
XWEL#41 XWELL Inc $7M PER - 
ADVB#42 Advanced Biomed Inc $5M PER - 
BIAF#43 BioAffinity Technologies Inc $4M PER - 
FAQ
What kind of company is MYNZ?
MYNZ belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MYNZ?
The market cap of MYNZ is approximately $8M, ranking 5,545 within its sector.
What is the 52-week high and low for MYNZ?
MYNZ has recorded a 52-week high of $5.34 and a low of $0.55.
